Purpose <p>This review seeks to offer an in-depth assessment of talazoparib, a highly effective PARP inhibitor, and its clinical uses in oncology. There is a special focus on pharmacokinetics, pharmacodynamics, safety, drug interaction, and licensed therapeutic uses, in addition to the incorporation of mechanistic data pertinent to its effectiveness. The purpose is to assist clinicians through clinical data.</p> Methods <p>The available literature was widely searched to identify studies between 2010 and 2024 using keywords such as “Talazoparib”, “Clinical Trials”, “PARP inhibitor”, and “treatment efficacy”. Both clinical and pre-clinical data were reviewed primarily from randomized controlled trials, observational studies, peer-reviewed articles, meta-analyses and clinical trial databases.</p> Results <p>The US Food and Drug Administration initially approved talazoparib, one of the most effective polyadenosine diphosphate ribose inhibitors, in October 2018 based on the phase-3 EMBRACA trial. It is preferred for HER-2 negative BRCA1/2 breast malignancies and for local castration-resistant prostate cancer (when combined with enzalutamide) due to its high efficacy with exposure and dynamic nature. Recent and current trials on talazoparib for the treatment of several neoplastic disorders, including ovarian cancer, have shown results warranting further clinical investigation.</p> Conclusion <p>Talazoparib has shown robust efficacy in BRCA1/2-mutated tumors and is already used in breast cancer and prostate cancer. It is being investigated in other solid tumors but its clinical application in those settings is still under investigation. Several challenges remain, such as the development of PARPi resistance. Its therapeutic use may expand through continuing clinical studies, particularly when used with other chemotherapeutic drugs.</p>